What we're reading, February 3, 2016: President Obama is asking Congress for $1.1 billion to combat the opioid abuse epidemic; 7 blockbuster drugs with the potential for more than $1 billion in sales each are expected in 2016; and less than half of infants are vaccinated against the flu.
The Obama administration is seeking $1.1 billion from Congress to combat the growing opioid abuse epidemic. The New York Times reported that half of the new money would expand treatment facilities, while the other half would go to programs intended to prevent overdoses and illegal sales, as well as improve access to naloxone, which can reverse the effects of an overdose. Both Republican and Democratic presidential candidates—including Republicans Chris Christie and Ben Carson, and Democrat Hillary Clinton—have spoken out about addressing the growing epidemic of prescription painkiller abuse.
In 2016, 7 “blockbuster” drugs are expected to reach market. Reuters reported that each drug is projected to have the potential for more than $1 billion in sales. The 2 biggest treatments anticipated are Intercept Pharmaceuticals’ chronic liver disease drug, and Gilead Sciences’ new fixed dose HIV drug. In 2015, there were 11 new blockbuster drugs.
Among babies between the ages of 6 months and 23 months, less than half are getting the flu vaccine, CDC reported. While the number of infants being vaccine has increased sharply from less than 5% in 2002-2003 to almost 45% in 2011-2012, the total still falls short of the CDC’s recommendation that children age 6 months and older get the flu shot every year, according to HealthDay. Every year, 20,000 children under the age of 5 years are hospitalized because of complications from the flu and during the 2014-2015 flu season, more than 140 children died from the flu.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More